NO329325B1 - Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser og diabetisk nefropati. - Google Patents

Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser og diabetisk nefropati. Download PDF

Info

Publication number: NO329325B1
Authority: NO; Norway
Prior art keywords: treatment; drugs; production; kidney function; use according
Prior art date: 1999-05-07

Application number

NO20015413A

Other languages

English (en)

Norwegian (no)

Other versions

NO20015413D0 (no

NO20015413L (no

Inventor

Hans-Jorg Treiber

Dorothea Starck

Bernd Muehlbauer

Gerhard Gross

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-07

Filing date

2001-11-06

Publication date

2010-09-27

2001-11-06 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2001-11-06 Publication of NO20015413D0 publication Critical patent/NO20015413D0/no

2001-11-15 Publication of NO20015413L publication Critical patent/NO20015413L/no

2010-09-27 Publication of NO329325B1 publication Critical patent/NO329325B1/no

Links

239000003814 drug Substances 0.000 title claims abstract description 17
238000004519 manufacturing process Methods 0.000 title claims abstract description 15
239000003446 ligand Substances 0.000 title claims abstract description 9
208000007342 Diabetic Nephropathies Diseases 0.000 title claims description 8
208000033679 diabetic kidney disease Diseases 0.000 title claims description 8
102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract description 14
108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract description 14
230000008085 renal dysfunction Effects 0.000 title description 2
229940079593 drug Drugs 0.000 claims abstract description 16
206010012601 diabetes mellitus Diseases 0.000 claims description 27
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
208000035475 disorder Diseases 0.000 claims description 14
230000003907 kidney function Effects 0.000 claims description 14
-1 propyl mercaptopyrimidin-4-ol fumarate Chemical compound 0.000 claims description 11
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 10
229940088353 Dopamine D3 receptor antagonist Drugs 0.000 claims description 6
230000001434 glomerular Effects 0.000 claims description 6
102000005962 receptors Human genes 0.000 claims description 5
108020003175 receptors Proteins 0.000 claims description 5
206010020880 Hypertrophy Diseases 0.000 claims description 4
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
230000001447 compensatory effect Effects 0.000 claims description 2
230000001174 ascending effect Effects 0.000 claims 1
230000004064 dysfunction Effects 0.000 claims 1
238000013059 nephrectomy Methods 0.000 claims 1
206010038464 renal hypertension Diseases 0.000 claims 1
208000007056 sickle cell anemia Diseases 0.000 claims 1
208000019206 urinary tract infection Diseases 0.000 claims 1
206010062237 Renal impairment Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 50
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 24
229910052736 halogen Inorganic materials 0.000 description 20
150000002367 halogens Chemical class 0.000 description 20
241001465754 Metazoa Species 0.000 description 19
125000001424 substituent group Chemical group 0.000 description 15
125000002947 alkylene group Chemical group 0.000 description 11
125000004432 carbon atom Chemical group C* 0.000 description 11
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 10
238000000034 method Methods 0.000 description 10
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 7
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
230000037396 body weight Effects 0.000 description 7
210000003734 kidney Anatomy 0.000 description 7
229960004940 sulpiride Drugs 0.000 description 7
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 6
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
125000002837 carbocyclic group Chemical group 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
125000000623 heterocyclic group Chemical group 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
229910052717 sulfur Inorganic materials 0.000 description 6
125000002373 5 membered heterocyclic group Chemical group 0.000 description 5
125000004070 6 membered heterocyclic group Chemical group 0.000 description 5
JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 5
108010081348 HRT1 protein Hairy Proteins 0.000 description 5
102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
230000024924 glomerular filtration Effects 0.000 description 4
239000008103 glucose Substances 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
125000006574 non-aromatic ring group Chemical group 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
206010001580 Albuminuria Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
125000001188 haloalkyl group Chemical group 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
201000001474 proteinuria Diseases 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
125000001544 thienyl group Chemical group 0.000 description 3
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
125000001054 5 membered carbocyclic group Chemical group 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
101100521345 Mus musculus Prop1 gene Proteins 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108700017836 Prophet of Pit-1 Proteins 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
150000001638 boron Chemical class 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 2
239000002300 dopamine 3 receptor blocking agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
150000002391 heterocyclic compounds Chemical class 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 description 2
230000007306 turnover Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
LCGFVWKNXLRFIF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-amine Chemical class C1=CC=C2CC(N)CCC2=C1 LCGFVWKNXLRFIF-UHFFFAOYSA-N 0.000 description 1
DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 description 1
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical class C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 1
UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
JARNORYOPMINDY-UHFFFAOYSA-N 4-(4-acetylphenyl)-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]benzamide Chemical compound COC1=CC=CC=C1N1CCN(CCCCNC(=O)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C(C)=O)CC1 JARNORYOPMINDY-UHFFFAOYSA-N 0.000 description 1
ZLBICQIZTNCOCN-UHFFFAOYSA-N 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine Chemical compound C1CN(CCCCN)CCN1C1=CC=CC(Cl)=C1Cl ZLBICQIZTNCOCN-UHFFFAOYSA-N 0.000 description 1
XILPCSMEKCBYFO-UHFFFAOYSA-N 4-methyl-1,2,4-triazole Chemical compound CN1C=NN=C1 XILPCSMEKCBYFO-UHFFFAOYSA-N 0.000 description 1
UPWQMWYEKFQIGO-UHFFFAOYSA-N 4-methyl-5-phenyl-1,2,4-triazole-3-carboxylic acid Chemical compound CN1C(C(O)=O)=NN=C1C1=CC=CC=C1 UPWQMWYEKFQIGO-UHFFFAOYSA-N 0.000 description 1
XZELWEMGWISCTP-UHFFFAOYSA-N 5-methoxy-1-benzofuran-2-carboxylic acid Chemical compound COC1=CC=C2OC(C(O)=O)=CC2=C1 XZELWEMGWISCTP-UHFFFAOYSA-N 0.000 description 1
125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000283707 Capra Species 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
238000005642 Gabriel synthesis reaction Methods 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
WJMAWNJIBUFYLV-UHFFFAOYSA-N NC(S1)=NN=C1[S+]=CCCCCCCCN(CC1)CCN1C1=CC=CC(C#N)=C1 Chemical compound NC(S1)=NN=C1[S+]=CCCCCCCCN(CC1)CCN1C1=CC=CC(C#N)=C1 WJMAWNJIBUFYLV-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010038468 Renal hypertrophy Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
UBLXEEBHYISRFM-UHFFFAOYSA-M folin's reagent Chemical compound [Na+].C1=CC=C2C(S(=O)(=O)[O-])=CC(=O)C(=O)C2=C1 UBLXEEBHYISRFM-UHFFFAOYSA-M 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000009760 functional impairment Effects 0.000 description 1
210000005086 glomerual capillary Anatomy 0.000 description 1
210000000585 glomerular basement membrane Anatomy 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000009588 inulin clearance Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
201000008627 kidney hypertrophy Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000012660 pharmacological inhibitor Substances 0.000 description 1
150000003008 phosphonic acid esters Chemical class 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 description 1
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
150000004867 thiadiazoles Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
229960002051 trandolapril Drugs 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

NO20015413A 1999-05-07 2001-11-06 Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser og diabetisk nefropati. NO329325B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19922443A DE19922443A1 (de)	1999-05-07	1999-05-07	Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
PCT/EP2000/003865 WO2000067847A2 (de)	1999-05-07	2000-04-28	Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen

Publications (3)

Publication Number	Publication Date
NO20015413D0 NO20015413D0 (no)	2001-11-06
NO20015413L NO20015413L (no)	2001-11-15
NO329325B1 true NO329325B1 (no)	2010-09-27

Family

ID=7908194

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015413A NO329325B1 (no)	1999-05-07	2001-11-06	Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser og diabetisk nefropati.

Country Status (19)

Country	Link
US (2)	US7098214B1 (cs)
EP (1)	EP1176963B1 (cs)
JP (3)	JP4727822B2 (cs)
KR (2)	KR100781828B1 (cs)
CN (2)	CN101524356A (cs)
AT (1)	ATE284693T1 (cs)
AU (1)	AU770671B2 (cs)
BR (1)	BR0010337A (cs)
CA (1)	CA2368823C (cs)
CZ (1)	CZ301832B6 (cs)
DE (2)	DE19922443A1 (cs)
DK (1)	DK1176963T3 (cs)
ES (1)	ES2234597T3 (cs)
HU (1)	HU228516B1 (cs)
IL (2)	IL146232A0 (cs)
NO (1)	NO329325B1 (cs)
PT (1)	PT1176963E (cs)
WO (1)	WO2000067847A2 (cs)
ZA (1)	ZA200110044B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19922443A1 (de) *	1999-05-07	2000-11-09	Basf Ag	Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
EP1223932A4 (en) *	1999-10-01	2003-01-15	Smithkline Beecham Corp	COMPOUNDS AND METHODS
US20020103198A1 (en) *	2000-12-04	2002-08-01	Fliri Anton F.J	Acylamino cyclopropane derivatives
EP1392676B1 (en) *	2001-02-16	2006-12-13	Aventis Pharmaceuticals Inc.	Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
ATE412638T1 (de)	2001-02-16	2008-11-15	Aventis Pharma Inc	Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
JP4497815B2 (ja) *	2001-02-16	2010-07-07	アベンティス・ファーマスーティカルズ・インコーポレイテツド	新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
DE10109866A1 (de) *	2001-03-01	2002-09-05	Abbott Gmbh & Co Kg	Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867A1 (de) *	2001-03-01	2002-09-05	Abbott Gmbh & Co Kg	Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
JP2005508841A (ja) *	2001-03-29	2005-04-07	スミスクライン・ビーチャム・コーポレイション	化合物および方法
DE10131543A1 (de) *	2001-06-29	2003-01-16	Abbott Lab	Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) *	2001-09-28	2004-11-29	Richter Gedeon Vegyeszet	Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
WO2003065871A2 (en) *	2002-02-04	2003-08-14	Millennium Pharmaceuticals Inc.	Methods and compositions for treating hematological disorders
ATE397755T1 (de) *	2003-03-17	2008-06-15	Bayer Healthcare Ag	Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US20050137186A1 (en)	2003-12-18	2005-06-23	Abbott Gmbh & Co. Kg.	Tetrahydrobenzazepines and their use
DE102004027358A1 (de)	2004-06-04	2005-12-29	Abbott Gmbh & Co. Kg	Pyrimidinverbindungen und ihre Verwendung
ES2340941T3 (es) *	2004-08-09	2010-06-11	ABBOTT GMBH & CO. KG	Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina.
CA2583983C (en)	2004-10-14	2013-07-16	Abbott Gmbh & Co. Kg	Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
BRPI0516115A (pt)	2004-10-14	2008-08-26	Abbott Gmbh & Co Kg	compostos arilsulfonilmetil ou arilsulfonamida aromáticos substituìdos adequados para tratar distúrbios que respondem à modulação do receptor de dopamina d3
US7759397B2 (en)	2004-10-14	2010-07-20	Abbott Gmbh & Co. Kg	6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ATE540922T1 (de)	2004-10-14	2012-01-15	Abbott Gmbh & Co Kg	Zur behandlung von erkrankungen, die auf eine modulation des dopamin-d3-rezeptors ansprechen, geeignete aminoethylaromatische verbindungen
US20070293548A1 (en) *	2006-03-31	2007-12-20	Wang Eric Y	Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
CN101522194B (zh) *	2006-08-04	2011-06-15	味之素株式会社	肾功能障碍预防/治疗剂
WO2009093471A1 (ja) *	2008-01-25	2009-07-30	Nihon University	アポトーシス抑制薬
KR20190028281A (ko)	2017-09-08	2019-03-18	주식회사 엑소코바이오	지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE628766A (cs) *	1962-12-26
GB1087514A (en) *	1965-04-09	1967-10-18	Hitachi Ltd	Arrangement for damping vibration of steam-turbine blades
DE4223921A1 (de)	1992-07-21	1994-01-27	Hartmut Prof Dr Med Oswald	Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) *	1996-01-12	1997-07-17	Basf Ag	Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) *	1999-05-07	2000-11-09	Basf Ag	Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

1999
- 1999-05-07 DE DE19922443A patent/DE19922443A1/de not_active Withdrawn
2000
- 2000-04-28 JP JP2000616868A patent/JP4727822B2/ja not_active Expired - Lifetime
- 2000-04-28 CN CNA2009100059907A patent/CN101524356A/zh active Pending
- 2000-04-28 AT AT00927101T patent/ATE284693T1/de active
- 2000-04-28 EP EP00927101A patent/EP1176963B1/de not_active Expired - Lifetime
- 2000-04-28 KR KR1020077007472A patent/KR100781828B1/ko not_active Expired - Fee Related
- 2000-04-28 DE DE50008964T patent/DE50008964D1/de not_active Expired - Lifetime
- 2000-04-28 HU HU0202399A patent/HU228516B1/hu unknown
- 2000-04-28 BR BR0010337-3A patent/BR0010337A/pt not_active IP Right Cessation
- 2000-04-28 ES ES00927101T patent/ES2234597T3/es not_active Expired - Lifetime
- 2000-04-28 AU AU45591/00A patent/AU770671B2/en not_active Expired
- 2000-04-28 CN CN008099774A patent/CN1360502B/zh not_active Expired - Lifetime
- 2000-04-28 CZ CZ20014015A patent/CZ301832B6/cs not_active IP Right Cessation
- 2000-04-28 PT PT00927101T patent/PT1176963E/pt unknown
- 2000-04-28 US US09/959,787 patent/US7098214B1/en not_active Expired - Lifetime
- 2000-04-28 DK DK00927101T patent/DK1176963T3/da active
- 2000-04-28 KR KR1020017014134A patent/KR20010112474A/ko not_active Ceased
- 2000-04-28 IL IL14623200A patent/IL146232A0/xx active IP Right Grant
- 2000-04-28 CA CA002368823A patent/CA2368823C/en not_active Expired - Lifetime
- 2000-04-28 WO PCT/EP2000/003865 patent/WO2000067847A2/de not_active Ceased
2001
- 2001-10-30 IL IL146232A patent/IL146232A/en not_active IP Right Cessation
- 2001-11-06 NO NO20015413A patent/NO329325B1/no not_active IP Right Cessation
- 2001-12-06 ZA ZA200110044A patent/ZA200110044B/xx unknown
2006
- 2006-06-16 US US11/424,739 patent/US8785447B2/en not_active Expired - Fee Related
2011
- 2011-02-08 JP JP2011025136A patent/JP5542713B2/ja not_active Expired - Lifetime
2014
- 2014-02-28 JP JP2014039287A patent/JP5897054B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL146232A (en)	2007-06-03
WO2000067847A3 (de)	2001-08-02
ES2234597T3 (es)	2005-07-01
US20060223793A1 (en)	2006-10-05
JP2014098044A (ja)	2014-05-29
KR20070040425A (ko)	2007-04-16
ZA200110044B (en)	2003-03-06
DE19922443A1 (de)	2000-11-09
BR0010337A (pt)	2002-02-13
CA2368823C (en)	2008-10-21
JP4727822B2 (ja)	2011-07-20
JP2002544178A (ja)	2002-12-24
KR100781828B1 (ko)	2007-12-03
HUP0202399A3 (en)	2003-02-28
JP2011088941A (ja)	2011-05-06
CA2368823A1 (en)	2000-11-16
EP1176963B1 (de)	2004-12-15
JP5542713B2 (ja)	2014-07-09
DE50008964D1 (de)	2005-01-20
EP1176963A2 (de)	2002-02-06
US8785447B2 (en)	2014-07-22
CZ301832B6 (cs)	2010-07-07
CZ20014015A3 (cs)	2002-02-13
PT1176963E (pt)	2005-05-31
CN1360502A (zh)	2002-07-24
HUP0202399A2 (hu)	2002-12-28
CN1360502B (zh)	2010-08-04
NO20015413D0 (no)	2001-11-06
AU4559100A (en)	2000-11-21
DK1176963T3 (da)	2005-04-25
AU770671B2 (en)	2004-02-26
HU228516B1 (en)	2013-03-28
ATE284693T1 (de)	2005-01-15
CN101524356A (zh)	2009-09-09
US7098214B1 (en)	2006-08-29
KR20010112474A (ko)	2001-12-20
NO20015413L (no)	2001-11-15
JP5897054B2 (ja)	2016-03-30
IL146232A0 (en)	2002-07-25
WO2000067847A2 (de)	2000-11-16

Legal Events

Date	Code	Title	Description
2014-06-02	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE
2020-05-11	MK1K	Patent expired

Publication	Publication Date	Title
NO329325B1 (no)	2010-09-27	Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser og diabetisk nefropati.
AU2001248324B2 (en)	2005-09-15	Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
RU2515968C2 (ru)	2014-05-20	5-членное гетероциклическое соединение и его применение для лекарственных целей
US6090807A (en)	2000-07-18	Use of heterocyclic compounds
RU2008135364A (ru)	2010-03-10	Соединения трехзамещенного амина и их применение в качестве ингибиторов белка переноса холестеринового эфира (сетр)
WO2005039549A1 (en)	2005-05-06	Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
WO2010037081A1 (en)	2010-04-01	Melanocortin receptor-specific spiro-piperidine compounds
JP2018520106A (ja)	2018-07-26	臓器障害の予防または処置のための化合物
CA2585983A1 (en)	2006-05-18	Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
CN113301921A (zh)	2021-08-24	治疗酪氨酸激酶抑制剂诱导的腹泻的方法
MXPA01011247A (es)	2002-06-05	Uso de ligandos del receptor d3 dopamina para la produccion de medicamentos para tratar trestornos del riñon
CN102958521A (zh)	2013-03-06	缓释性高血压和肾功能不全治疗剂
JP2004525904A (ja)	2004-08-26	線維性疾患又は他の適応症ｉｉｉｃの治療方法
CN117479939A (zh)	2024-01-30	用于治疗红细胞增多症的组合物和方法
JPWO1998014213A1 (ja)	2000-01-18	ミトコンドリア膜安定化剤
WO2012115226A1 (ja)	2012-08-30	癌治療剤